Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
The following patients with diabetes mellitus type 2 who can give written consent will be eligible for enrollment. They must meet all criteria.
- > 21 years of age
- Body mass index (BMI) ≥30 kg/m2
- On insulin at least 2 times daily comprising both a basal and a prandial insulin or a pre-mix insulin with or without other non-insulin medications for a least past 3 months
- A1c >8%
- eGFR >45%
Exclusion Criteria:
The patients with any of the following criteria will be excluded.
- Any patient who does not meet the above inclusion criteria.
- Pregnancy
- Patients who are on a SGLT2i and a GLP1 RA injection at the time of enrollment.
- diabetes mellitus type 1
- C-peptide below normal range if measured in the past.
- patients with a history of diabetes ketoacidosis
- A history of recent and frequent (≥ 2 times within past 3 months) urinary tract infection or genito-urinary candidiasis requiring antibiotic and/or anti-fungal therapies.
- a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- eGFR <45%
- patients with a history of acute pancreatitis
Sites / Locations
- UCSF Fresno
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Treatment group
Control group
Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.